Biopsy DNA Research Articles

96 The effect of embryo stage and biopsy on embryo viability

Abstract The importance of embryo biopsy is running a 50K genomic test will be completed on the DNA biopsy, giving us the ability to collect genetic prediction data before the calf is even born. The objective of this study was to compare the viability of bovine embryos (n = 24) at different stages of embryo maturation, after microblade biopsy and embryo transfer. This process was achieved by taking a small biopsy of each embryo. The results of aspirating oocytes from packing house ovaries and in vitro fertilization (IVF), within a 48 h time period marked d 0. After a 7-d incubation period, the results consisted of 14 blastocysts and 10 early blastocysts. The final sample size, of 24 embryos, differing in stages between early blastocyst (TRT 6) and blastocyst (TRT 7). All the embryos, except for one, was a Grade 1 embryo. On d 7 the embryos were grouped by stage of embryo. Each embryo was washed, and biopsied with a microblade by a single technician. After the biopsy, the embryos were incubated for a 24 h period. Immediately after the incubation period, each embryo was analyzed for viability. On d 8, TRT 7 embryos had a 50% viability rate (n = 7), whereas TRT 6 embryos had a 70% viability rate (n = 7). Data were analyzed using GLIMMIX procedure of SAS 9.4. The viability did not differ between either treatment (P = 0.58). However, the biopsy of each embryo resulted in a significant effect on embryo viability (P < 0.01). In conclusion, using embryo biopsy and the stage of the embryo may affect embryo viability.

Personalized oncology: the potential for tissue and cell-free DNA biopsies to capture tumor heterogeneity

Personalized oncology: the potential for tissue and cell-free DNA biopsies to capture tumor heterogeneity

Better detection of Ig heavy chain and TCRγ gene rearrangement in plasma cell-free DNA from patients with non-Hodgkin Lymphoma

Plasma cell-free DNA is the soluble DNA and tumor-derived DNA in plasma which has the same mutation as the tumor cellular DNA. This study aimed at comparing the properties of plasma cell-free DNA with the biopsy's DNA in order to evaluate the clinical significance of IgH and TCRγ gene rearrangement in plasma cell-free DNA from patients with non-Hodgkin's Lymphoma. A total of 360 samples were studied. IgH (FR3A/VLJH) and TCRγ (TVG/TJX) were amplified by PCR. Results of plasma cell-free DNA were compared with biopsy's DNA and mononuclear cellular DNA respectively. Plasma cell-free DNA were successfully extracted from 288 cases of newly diagnosed, refractory and relapsed NHL in total 360 patients (80%).But nothing was found in the other 72 remittent patients. The positive percentage of IgH rearrangement in patients with B-NHL was 81% in plasma cell-free DNA and 77% in biopsy's DNA (P>0.05). As to the ratio of TCRγ rearrangement in patients with T-NHL, the former was 44%, and the latter was 39% (P>0.05). These results show tumor-derived DNA could be detected in tumor loaded plasma, even of underlying cancer patients. For NHL patients, detecting IgH and TCRγ gene rearrangement of plasma cell-free DNA has the same clinical significance as biopsy's DNA. Moreover, it's more simple, convenient and non-invasive. Lymphoma non-Hodgkin, plasma, cell-free DNA, gene rearrangement, immunoglobulin, heavy-chain gene, T-cell receptor.γ

Microsatellite instability as an indicator of malignant progression in laryngeal premalignancy

Microsatellite instability (MSI) is considered a novel marker of genetic instability, and preliminary studies have shown that it may provide useful information in assessing the risk of malignant progression in preinvasive lesions. We analyzed MSI in serial biopsy specimens from 10 patients with preinvasive laryngeal lesions and corresponding metachronous laryngeal cancers compared with biopsy specimens of similar lesions without malignant transformation from 20 subjects in a match-paired analysis. MSI was determined by assessing the status of 14 microsatellite markers (chromosome loci: 2p16, 3q21-24, 4q12, 9p21, 13q14, 16q22.1, 17p12 and 21q21) in DNA biopsy specimens. MSI(+) (aberration at two or more loci) was detected in seven of 10 patients with premalignant lesions progressed to carcinoma, whereas only four of the 20 biopsy specimens from control subjects showed an unstable phenotype (p < .01). Interestingly, preinvasive laryngeal lesions with MSI at hMSH2/hMSH6 loci frequently had instability at one or more additional loci and were considered as MSI(+) (overall in eight of 12 cases: six premalignant lesions progressed to cancer and one without progression of the original laryngeal lesion, p < .01). The immunohistochemical analysis of the hMSH2 protein expression in our series, however, did not suggest its involvement in laryngeal carcinogenesis. Our study indicates that MSI is more common in preneoplastic laryngeal lesions progressing to cancer, thus suggesting that microsatellite status assessment may be useful in determining the risk of malignant progression in patients with preinvasive laryngeal lesions for whom chemopreventive and multiple endoscopic protocols can be attempted.